Next Article in Journal
Lymphedema in Canada: A Qualitative Study to Help Develop a Clinical, Research, and Education Strategy
Previous Article in Journal
The igf System in Carcinogenesis and Its Implication for Cancer Therapy
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 18
Issue 6
10.3747/co.v18is2.939
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Corrigendum: Progression-Free Survival in Advanced Ovarian Cancer: A Canadian Review and Expert Panel Perspective

by
A.M. Oza
1,
V. Castonguay
1,
D. Tsoref
1,
I. Diaz–Padilla
1,
K. Karakasis
1,
H. Mackay
1,
S. Welch
2,
J. Weberpals
3,
P. Hoskins
4,
M. Plante
5,
D. Provencher
6,
K. Tonkin
7,
A. Covens
8,
P. Ghatage
9,
J. Gregoire
10,
H. Hirte
11,
D. Miller
4,
B. Rosen
1,
J. Bentley
12,
J. Maroun
3,
M. Buyse
10,
C. Coens
13,
M.F. Brady
14 and
G.C.E. Stuart
15add Show full author list remove Hide full author list
1
Princess Margaret Hospital, Toronto, ON,
2
London Health Sciences Centre, London, ON, Canada
3
The Ottawa Hospital, Ottawa, ON, Canada
4
BC Cancer Agency, Vancouver, BC, Canada
5
Department of Obstetrics and Gynecology, Laval University, Laval, QC, Canada
6
Division of Gynecologic Oncology, Université de Montréal, Institut du Cancer de Montréal, Centre Recherche CHUM, Montreal, QC, Canada
7
Cross Cancer Institute, Edmonton, AB, Canada
8
Toronto–Sunnybrook Regional Cancer Centre, Toronto, ON, Canada
9
Tom Baker Cancer Centre, Calgary, AB, Canada
10
CHUQ–Hotel-Dieu de Quebec, Quebec City, QC, Canada
11
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, ON, Canada
12
Division of Gynecologic Oncology, Dalhousie University, Halifax, NS, Canada
13
European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium
14
Roswell Park Cancer Institute, Buffalo, NY, USA
15
University of British Columbia, Vancouver, BC, Canada
 
add Show full affiliation list
 
remove Hide full affiliation list
Curr. Oncol. 2011, 18(6), 303; https://doi.org/10.3747/co.v18is2.939
Submission received: 7 November 2011 / Revised: 13 November 2011 / Accepted: 14 November 2011 / Published: 1 December 2011

Abstract

In recent years, significant advances have been made in the management of metastatic colorectal cancer. Traditionally, an improvement in overall survival has been considered the “gold standard”—the most convincing measure of efficacy. However, overall survival requires larger patient numbers and longer follow-up and may often be confounded by other factors, including subsequent therapies and crossover. Given the number of active therapies for potential investigation, demand for rapid evaluation and early availability of new therapies is growing. Progression-free survival is regarded as an important measure of treatment benefit and, compared with overall survival, can be evaluated earlier, with fewer patients and no confounding by subsequent lines of therapy. The present paper reviews the advantages, limitations, and relevance of progression-free survival as a primary endpoint in randomized trials of metastatic colorectal cancer.
Keywords: progression-free survival; metastatic colorectal cancer; surrogate endpoints; targeted therapies; randomized clinical trials progression-free survival; metastatic colorectal cancer; surrogate endpoints; targeted therapies; randomized clinical trials

Share and Cite

MDPI and ACS Style

Oza, A.M.; Castonguay, V.; Tsoref, D.; Diaz–Padilla, I.; Karakasis, K.; Mackay, H.; Welch, S.; Weberpals, J.; Hoskins, P.; Plante, M.; et al. Corrigendum: Progression-Free Survival in Advanced Ovarian Cancer: A Canadian Review and Expert Panel Perspective. Curr. Oncol. 2011, 18, 303. https://doi.org/10.3747/co.v18is2.939

AMA Style

Oza AM, Castonguay V, Tsoref D, Diaz–Padilla I, Karakasis K, Mackay H, Welch S, Weberpals J, Hoskins P, Plante M, et al. Corrigendum: Progression-Free Survival in Advanced Ovarian Cancer: A Canadian Review and Expert Panel Perspective. Current Oncology. 2011; 18(6):303. https://doi.org/10.3747/co.v18is2.939

Chicago/Turabian Style

Oza, A.M., V. Castonguay, D. Tsoref, I. Diaz–Padilla, K. Karakasis, H. Mackay, S. Welch, J. Weberpals, P. Hoskins, M. Plante, and et al. 2011. "Corrigendum: Progression-Free Survival in Advanced Ovarian Cancer: A Canadian Review and Expert Panel Perspective" Current Oncology 18, no. 6: 303. https://doi.org/10.3747/co.v18is2.939

APA Style

Oza, A. M., Castonguay, V., Tsoref, D., Diaz–Padilla, I., Karakasis, K., Mackay, H., Welch, S., Weberpals, J., Hoskins, P., Plante, M., Provencher, D., Tonkin, K., Covens, A., Ghatage, P., Gregoire, J., Hirte, H., Miller, D., Rosen, B., Bentley, J., ... Stuart, G. C. E. (2011). Corrigendum: Progression-Free Survival in Advanced Ovarian Cancer: A Canadian Review and Expert Panel Perspective. Current Oncology, 18(6), 303. https://doi.org/10.3747/co.v18is2.939

Article Metrics

Back to TopTop